FDA-approved Mounjaro (tirzepatide) is a GLP-1 medication used for treating diabetes in adults who have a body mass index (BMI) over 27, have hypertension or dyslipidemia, or are obese ( BMI over 30)
Decide if you want a baseline reading (without supplements) or a "progress" reading (while on your routine)
Protocols commonly use 200500 mcg subcutaneously, once or twice daily, in 46 week cycles, but there is no FDA-approved product or official dosing
20% weight on overall vendor reputation pulled from the published formula across shipping, transparency, tenure, and lab credibility broadly
: , , , -157 - ,
Local and Theoretical Concerns Local reactions observed or theoretically expected in animal models include: Transient erythema at topical application sites Mild irritation or inflammatory responses at injection sites Potential for altered MMP activity with excessive dosing Theoretical risk of excessive collagen degradation if matrix enzyme balance is disrupted The concern about copper toxicityvalid for free copper ionsappears mitigated by the peptides chelation mechanism